SE0402735D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0402735D0
SE0402735D0 SE0402735A SE0402735A SE0402735D0 SE 0402735 D0 SE0402735 D0 SE 0402735D0 SE 0402735 A SE0402735 A SE 0402735A SE 0402735 A SE0402735 A SE 0402735A SE 0402735 D0 SE0402735 D0 SE 0402735D0
Authority
SE
Sweden
Prior art keywords
novel compounds
therapy
processes
pharmaceutically acceptable
formula
Prior art date
Application number
SE0402735A
Other languages
English (en)
Inventor
Malena Bengtsson
Joakim Larsson
Grigorios Nikitidis
Peter Storm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0402735A priority Critical patent/SE0402735D0/sv
Publication of SE0402735D0 publication Critical patent/SE0402735D0/sv
Priority to EP05801592A priority patent/EP1841763B1/en
Priority to CNA2005800461365A priority patent/CN101098869A/zh
Priority to DE602005022116T priority patent/DE602005022116D1/de
Priority to AT05801592T priority patent/ATE472546T1/de
Priority to US11/667,064 priority patent/US7868188B2/en
Priority to BRPI0517634-4A priority patent/BRPI0517634A/pt
Priority to JP2007539638A priority patent/JP2008519021A/ja
Priority to PCT/GB2005/004268 priority patent/WO2006051270A1/en
Priority to AU2005303566A priority patent/AU2005303566A1/en
Priority to ES05801592T priority patent/ES2346333T3/es
Priority to CA002585310A priority patent/CA2585310A1/en
Priority to MX2007005546A priority patent/MX2007005546A/es
Priority to KR1020077012802A priority patent/KR20070085837A/ko
Priority to UY29199A priority patent/UY29199A1/es
Priority to TW094139209A priority patent/TW200621762A/zh
Priority to ARP050104699A priority patent/AR052232A1/es
Priority to IL182726A priority patent/IL182726A0/en
Priority to NO20072259A priority patent/NO20072259L/no
Priority to ZA200703714A priority patent/ZA200703714B/xx
Priority to HK08101781.3A priority patent/HK1112895A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
SE0402735A 2004-11-09 2004-11-09 Novel compounds SE0402735D0 (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE0402735A SE0402735D0 (sv) 2004-11-09 2004-11-09 Novel compounds
KR1020077012802A KR20070085837A (ko) 2004-11-09 2005-11-07 5-헤테로아릴 티아졸 및 이것의 ｐｉ3ｋ 억제제로서의 용도
PCT/GB2005/004268 WO2006051270A1 (en) 2004-11-09 2005-11-07 5-heteroaryl thiazoles and their use as p13k inhibitors
ES05801592T ES2346333T3 (es) 2004-11-09 2005-11-07 5-heteroaril tiazoles y su uso como inhibidores de pi3k.
DE602005022116T DE602005022116D1 (de) 2004-11-09 2005-11-07 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren
AT05801592T ATE472546T1 (de) 2004-11-09 2005-11-07 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren
US11/667,064 US7868188B2 (en) 2004-11-09 2005-11-07 5-heteroaryl thiazoles and their use as PI3K inhibitors
BRPI0517634-4A BRPI0517634A (pt) 2004-11-09 2005-11-07 derivado de tiazol ou um derivado farmaceuticamente aceitável do mesmo, processo para a preparação de um composto, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
JP2007539638A JP2008519021A (ja) 2004-11-09 2005-11-07 ５−ヘテロアリールチアゾール及びｐｉ３ｋ阻害剤としてのその使用
EP05801592A EP1841763B1 (en) 2004-11-09 2005-11-07 5-heteroaryl thiazoles and their use as pi3k inhibitors
AU2005303566A AU2005303566A1 (en) 2004-11-09 2005-11-07 5-heteroaryl thiazoles and their use as P13K inhibitors
CNA2005800461365A CN101098869A (zh) 2004-11-09 2005-11-07 5-杂芳基噻唑及其作为磷脂酰肌醇3-激酶抑制剂的用途
CA002585310A CA2585310A1 (en) 2004-11-09 2005-11-07 5-heteroaryl thiazoles and their use as p13k inhibitors
MX2007005546A MX2007005546A (es) 2004-11-09 2005-11-07 Tiazoles de 5-heteroarilo y su uso como inhibidores p13k.
UY29199A UY29199A1 (es) 2004-11-09 2005-11-08 Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
TW094139209A TW200621762A (en) 2004-11-09 2005-11-09 Novel compounds
ARP050104699A AR052232A1 (es) 2004-11-09 2005-11-09 Derivados de 5-heteroariltiazoles
IL182726A IL182726A0 (en) 2004-11-09 2007-04-22 5-heteroaryl thiazoles and their use as p13k inhibitors
NO20072259A NO20072259L (no) 2004-11-09 2007-04-30 Heteroaryltiazoler og deres anvendelse som P13K-inhibitorer
ZA200703714A ZA200703714B (en) 2004-11-09 2007-05-08 5-heteroaryl thiazoles and their use as P13K inhibitors
HK08101781.3A HK1112895A1 (en) 2004-11-09 2008-02-19 5-heteroaryl thiazoles and their use as pi3k inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0402735A SE0402735D0 (sv) 2004-11-09 2004-11-09 Novel compounds

Publications (1)

Publication Number Publication Date
SE0402735D0 true SE0402735D0 (sv) 2004-11-09

Family

ID=33488202

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0402735A SE0402735D0 (sv) 2004-11-09 2004-11-09 Novel compounds

Country Status (21)

Country Link
US (1) US7868188B2 (sv)
EP (1) EP1841763B1 (sv)
JP (1) JP2008519021A (sv)
KR (1) KR20070085837A (sv)
CN (1) CN101098869A (sv)
AR (1) AR052232A1 (sv)
AT (1) ATE472546T1 (sv)
AU (1) AU2005303566A1 (sv)
BR (1) BRPI0517634A (sv)
CA (1) CA2585310A1 (sv)
DE (1) DE602005022116D1 (sv)
ES (1) ES2346333T3 (sv)
HK (1) HK1112895A1 (sv)
IL (1) IL182726A0 (sv)
MX (1) MX2007005546A (sv)
NO (1) NO20072259L (sv)
SE (1) SE0402735D0 (sv)
TW (1) TW200621762A (sv)
UY (1) UY29199A1 (sv)
WO (1) WO2006051270A1 (sv)
ZA (1) ZA200703714B (sv)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
AU2006244206A1 (en) 2005-05-10 2006-11-16 Vertex Pharmaceuticals Incorporated Bicyclic derivatives as modulators of ion channels
CA2608153C (en) 2005-05-24 2014-09-23 Laboratoires Serono S.A. Thiazole derivatives for use as p13k modulators
BRPI0706621A2 (pt) 2006-01-18 2011-04-05 Amgen Inc composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto
US20090029997A1 (en) * 2006-01-23 2009-01-29 Laboratoires Serono Sa Thiazole Derivatives and Use Thereof
CA2640090A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
EP2007393B1 (en) * 2006-04-07 2013-08-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
JP2009535386A (ja) * 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ チアゾール誘導体および抗腫瘍剤としてのその使用
ATE414281T1 (de) * 2006-08-03 2008-11-15 Cellzome Ag Verfahren zur identifizierung von molekülen die mit pi3k interagieren und verfahren zur reinigung von pi3k
AU2007290359B2 (en) * 2006-09-01 2012-09-20 Vertex Pharmaceuticals Incorporated 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
GB0620059D0 (en) * 2006-10-10 2006-11-22 Ucb Sa Therapeutic agents
GB0620818D0 (en) * 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
US8263585B2 (en) 2007-05-04 2012-09-11 Novartis Ag Organic compounds
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
US7919504B2 (en) 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
ES2394126T3 (es) * 2007-07-26 2013-01-22 Novartis Ag Derivados de pirimidina útiles para el tratamiento de estados inflamatorios o alérgicos
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
US20100311736A1 (en) * 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
EP2231661A1 (en) 2007-12-19 2010-09-29 Amgen, Inc. Inhibitors of pi3 kinase
CN101952282A (zh) 2007-12-20 2011-01-19 诺瓦提斯公司 用作pi 3激酶抑制剂的噻唑衍生物
ATE528408T1 (de) * 2008-02-04 2011-10-15 Cellzome Ag Selektivitätsprofilerstellung von mit pi3k wechselwirkenden molekülen gegen mehrere ziele
JP2011515369A (ja) * 2008-03-19 2011-05-19 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト 殺菌剤ヒドロキシモイル−テトラゾール誘導体
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
WO2009158376A1 (en) * 2008-06-26 2009-12-30 Smithkline Beecham Corporation Inhibitors of akt activity
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
US20110135655A1 (en) * 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
US20120039905A1 (en) * 2009-01-13 2012-02-16 The Babraham Institute The Role of p110 delta Signaling in Morbidity and Lung Pathology Induced by Influenza Virus Infection
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
SI2414369T1 (sl) 2009-04-02 2015-12-31 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Derivati imidazo(2,1-b)(1,3,4)tiadiazola
US20120071475A1 (en) * 2009-04-27 2012-03-22 Shionogi & Co., Ltd. Urea derivatives having pi3k-inhibiting activity
MA33358B1 (fr) 2009-05-15 2012-06-01 Novartis Ag Arylpyridine en tant qu'inhibiteurs de l'aldostérone synthase
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
UY32748A (es) 2009-07-02 2011-01-31 Novartis Ag 2-carboxamida-cicloamino-ureas
US20130209487A1 (en) * 2010-07-07 2013-08-15 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Treatment of Avian Species with Inhibitors of P110 Delta Signaling
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
JP5648058B2 (ja) * 2010-07-22 2015-01-07 扶桑薬品工業株式会社 ベンゾフラノン化合物およびそれを含む医薬組成物
WO2012035171A2 (en) * 2010-09-17 2012-03-22 Kancera Ab New compounds
MX364378B (es) 2011-08-30 2019-01-21 Chdi Foundation Inc Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso.
US9926309B2 (en) 2011-10-05 2018-03-27 The Board Of Trustees Of The Leland Stanford Junior University Pi-kinase inhibitors with anti-infective activity
EP2763532B1 (en) 2011-10-05 2018-09-19 The Board of Trustees of the Leland Stanford Junior University Pi-kinase inhibitors with broad spectrum anti-infective activity
KR102083041B1 (ko) 2012-02-22 2020-05-27 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 술폰아미드 화합물 및 ｔｎａｐ 억제제로서 용도
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
EP2914260A1 (en) * 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
US9567310B2 (en) 2012-11-09 2017-02-14 Inserm (Institut National De La Sante Et De La Recharche Medicale) Benzene sulfonamide thiazole compounds
EP2988744A4 (en) 2013-04-26 2016-11-02 Merck Sharp & Dohme THIAZOLE SUBSTITUTED AMINOHETEROARYL COMPOUNDS TYLOSINE KINASE SPLENIC INHIBITORS
US9822107B2 (en) 2013-12-20 2017-11-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3083560B1 (en) 2013-12-20 2021-10-27 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015094997A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
GEP20196983B (en) 2014-01-14 2019-06-25 Millennium Pharm Inc Heteroaryls and uses thereof
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP3116506B1 (en) 2014-03-13 2019-04-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
CN104016910A (zh) * 2014-04-03 2014-09-03 定陶县友帮化工有限公司 一种2-氨基-3-氯-5-溴吡啶的合成方法
MX2017000779A (es) 2014-07-17 2017-07-27 Chdi Foundation Inc Metodos y composiciones para el tratamiento de trastornos relacionados con el vih.
CN104844589B (zh) * 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
EP3419980A4 (en) 2016-02-26 2019-07-03 The Board of Trustees of the Leland Stanford Junior University INHIBITORS OF PI-KINASE WITH ANTI-INFECTIOUS ACTIVITY
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
EP3842439A4 (en) 2018-08-21 2022-04-27 Kyorin Pharmaceutical Co., Ltd. BICYCLIC HETEROAROMATIC RING DERIVATIVE
CA3164264A1 (en) 2020-01-02 2021-07-08 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Novel pqsr inverse agonists
CN116531373A (zh) * 2022-01-26 2023-08-04 上海日馨医药科技股份有限公司 噻唑类化合物、其药物组合物及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8302591D0 (en) * 1983-01-31 1983-03-02 Fujisawa Pharmaceutical Co Thiazole derivatives
US4649146A (en) * 1983-01-31 1987-03-10 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives and pharmaceutical composition comprising the same
AUPP873799A0 (en) * 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
PE20030968A1 (es) 2002-02-28 2004-01-12 Novartis Ag Derivados de 5-feniltiazol como inhibidores de cinasas
GB0305152D0 (en) * 2003-03-06 2003-04-09 Novartis Ag Organic compounds
TW200519106A (en) * 2003-05-02 2005-06-16 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1841763A1 (en) 2007-10-10
ES2346333T3 (es) 2010-10-14
UY29199A1 (es) 2006-06-30
AR052232A1 (es) 2007-03-07
CA2585310A1 (en) 2006-05-18
KR20070085837A (ko) 2007-08-27
HK1112895A1 (en) 2008-09-19
BRPI0517634A (pt) 2008-10-14
MX2007005546A (es) 2007-06-19
IL182726A0 (en) 2007-07-24
WO2006051270A1 (en) 2006-05-18
NO20072259L (no) 2007-06-06
AU2005303566A1 (en) 2006-05-18
TW200621762A (en) 2006-07-01
CN101098869A (zh) 2008-01-02
DE602005022116D1 (de) 2010-08-12
ZA200703714B (en) 2008-09-25
JP2008519021A (ja) 2008-06-05
ATE472546T1 (de) 2010-07-15
US20080132502A1 (en) 2008-06-05
EP1841763B1 (en) 2010-06-30
US7868188B2 (en) 2011-01-11

Similar Documents

Publication Publication Date Title
SE0402735D0 (sv) Novel compounds
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
NO20071703L (no) Kinazolinderivater
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
NO20090631L (no) Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
EA201000090A1 (ru) Тризамещенные производные пиримидина для лечения пролиферативных заболеваний
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
UY30183A1 (es) Derivados de quinolina
TW200700392A (en) Novel compounds
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
TW200639156A (en) New compounds
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
SE0401762D0 (sv) Novel compounds